Mon, Sep 22, 2014, 6:14 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Affymax, Inc. (AFFY) Message Board

  • jagan1961 jagan1961 Apr 30, 2013 10:21 PM Flag

    Another garbage from bashers, New Trial??

    What else would you expect from them? New trial for an approved drug, administered to frail of frail patients.

    Add one more fear, wow! What further from them, longs will never have that kind of imagination!

    Sentiment: Hold

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I am not adding any new fears. You are just not paying any attention to publicly disclosed facts that might interfere with your rose colored glasses outlook about Affymax/Takeda and Omontys. From Affymax's April 2, 2013 press release, Affymax disclosed "discussions with the FDA including a potential withdrawal of the OMONTYS New Drug Application (NDA)..." What happens when O's NDA is voluntarily withdrawn? Takeda could resubmit later, and more than likely will, but supported by a study that addresses the FDA safety concerns. From an earlier NY Times article concerning the recall of Omontys: "Dr. Ajay K. Singh, a kidney specialist at Brigham and Women’s Hospital in Boston, said that the recall should result in “minimal disruption” because centers could use Epogen or another Amgen drug, Aranesp. But he said it might be hard for Affymax and Takeda, which is based in Osaka, to show the safety of their drug without a huge study."

      You see jagan, I do not make stuff up like the long pumpers do. I happen to pay attention to what has already been publicly disclosed and make reasonable and logical inferences from these facts. I am sorry if it interferes with your dreams of quick and spectacular gains from owning stock in a failed and still failing Affymax.

      • 1 Reply to godwinpeak
      • "discussions with the FDA including a potential withdrawal of the OMONTYS New Drug Application (NDA)..."

        --You need to look up the definition of potential. This is not a fact as you say. If it actually does happen then that will be a fact.

        "Dr. Ajay K. Singh, a kidney specialist at Brigham and Women’s Hospital in Boston, said that the recall should result in “minimal disruption” because centers could use Epogen or another Amgen drug, Aranesp. But he said it might be hard for Affymax and Takeda, which is based in Osaka, to show the safety of their drug without a huge study."

        "it might be hard for Affymax and Takeda"

        ---You should also look up the word "might". That is also not a fact. In other words, this one is an opinion.

        So are these the publicly disclosed "facts" you are speaking of.

        The main facts which I am aware of (and they are facts) are .00012% (3 out of 25000) patients who took Omontys died from anaphylactic shock which is an allergic reaction you can also get from X-rays, antibiotics, aspirin, Advil, Aleve, penicillin, peanuts, shellfish, latex, wheat, fish, milk, eggs, a bee sting, anesthesia, sesame, chickpeas etc!!! My opinion is that it will not be very difficult to test for allergic reactions either through a skin or blood test in addition to whatever additional precautions they need to take when administering the drug.

        These opinions and perceptions which you pawn off as truths may be holding the stock down at the moment so you can gloat, give yourself a high five, smell your own farts or whatever it is you do each day getting your jollies on this board, but I'll say your bet on .00012% will eventually lose.

        I'm not sure if we can completely blame you for not knowing the difference between an opinion and a truth... you were a lawyer weren't you? The most trusted profession in the world. LOL

 
AFFY
0.16-0.01(-5.88%)Sep 22 3:52 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.